Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Can leukocyte telomere shortening be a possible biomarker to track Huntington's disease progression?

Mantuano E, Peconi M, Scarabino D.

Neural Regen Res. 2019 Oct;14(10):1709-1710. doi: 10.4103/1673-5374.257522. No abstract available.

2.

Leukocyte telomere shortening in Huntington's disease.

Scarabino D, Veneziano L, Peconi M, Frontali M, Mantuano E, Corbo RM.

J Neurol Sci. 2019 Jan 15;396:25-29. doi: 10.1016/j.jns.2018.10.024. Epub 2018 Oct 28.

PMID:
30396032
3.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

PMID:
28642124
4.

An image-based model of brain volume biomarker changes in Huntington's disease.

Wijeratne PA, Young AL, Oxtoby NP, Marinescu RV, Firth NC, Johnson EB, Mohan A, Sampaio C, Scahill RI, Tabrizi SJ, Alexander DC.

Ann Clin Transl Neurol. 2018 Apr 2;5(5):570-582. doi: 10.1002/acn3.558. eCollection 2018 May.

5.

Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.

Aylward EH.

Mov Disord. 2014 Sep 15;29(11):1429-33. doi: 10.1002/mds.26013. Epub 2014 Aug 27. Review.

6.

Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood.

Mastrokolias A, Ariyurek Y, Goeman JJ, van Duijn E, Roos RA, van der Mast RC, van Ommen GB, den Dunnen JT, 't Hoen PA, van Roon-Mom WM.

Eur J Hum Genet. 2015 Oct;23(10):1349-56. doi: 10.1038/ejhg.2014.281. Epub 2015 Jan 28.

7.

Telomere shortening and accelerated aging in COPD: findings from the BODE cohort.

Córdoba-Lanús E, Cazorla-Rivero S, Espinoza-Jiménez A, de-Torres JP, Pajares MJ, Aguirre-Jaime A, Celli B, Casanova C.

Respir Res. 2017 Apr 13;18(1):59. doi: 10.1186/s12931-017-0547-4. Erratum in: Respir Res. 2017 Jun 2;18(1):113.

8.

Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.

Hoss AG, Lagomarsino VN, Frank S, Hadzi TC, Myers RH, Latourelle JC.

Mov Disord. 2015 Dec;30(14):1961-4. doi: 10.1002/mds.26457. Epub 2015 Nov 17.

9.

Validation of a prognostic index for Huntington's disease.

Long JD, Langbehn DR, Tabrizi SJ, Landwehrmeyer BG, Paulsen JS, Warner J, Sampaio C.

Mov Disord. 2017 Feb;32(2):256-263. doi: 10.1002/mds.26838. Epub 2016 Nov 28.

10.

Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease.

Harrington DL, Long JD, Durgerian S, Mourany L, Koenig K, Bonner-Jackson A, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group, Rao SM.

Mov Disord. 2016 Nov;31(11):1664-1675. doi: 10.1002/mds.26803. Epub 2016 Sep 13.

11.

Reduced telomere length in neurodegenerative disorders may suggest shared biology.

Kota LN, Bharath S, Purushottam M, Moily NS, Sivakumar PT, Varghese M, Pal PK, Jain S.

J Neuropsychiatry Clin Neurosci. 2015;27(2):e92-6. doi: 10.1176/appi.neuropsych.13100240. Epub 2014 Dec 26.

PMID:
25541866
12.

Molecular Imaging Markers to Track Huntington's Disease Pathology.

Wilson H, De Micco R, Niccolini F, Politis M.

Front Neurol. 2017 Jan 30;8:11. doi: 10.3389/fneur.2017.00011. eCollection 2017. Review.

13.

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.

Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ.

Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

14.

Huntington's disease.

Ha AD, Fung VS.

Curr Opin Neurol. 2012 Aug;25(4):491-8. doi: 10.1097/WCO.0b013e3283550c97. Review.

PMID:
22772878
15.

Telomere longitudinal shortening as a biomarker for dementia status of adults with Down syndrome.

Jenkins EC, Ye L, Krinsky-McHale SJ, Zigman WB, Schupf N, Silverman WP.

Am J Med Genet B Neuropsychiatr Genet. 2016 Mar;171B(2):169-74. doi: 10.1002/ajmg.b.32389. Epub 2015 Nov 23.

PMID:
26593971
16.

Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?

Shin H, Kim MH, Lee SJ, Lee KH, Kim MJ, Kim JS, Cho JW.

J Clin Neurol. 2013 Jan;9(1):21-5. doi: 10.3988/jcn.2013.9.1.21. Epub 2013 Jan 3.

17.

Oxidative Stress-induced Telomere Length Shortening of Circulating Leukocyte in Patients with Obstructive Sleep Apnea.

Kim KS, Kwak JW, Lim SJ, Park YK, Yang HS, Kim HJ.

Aging Dis. 2016 Oct 1;7(5):604-613. eCollection 2016 Oct.

18.

Spectral-Domain Optical Coherence Tomography as a Potential Biomarker in Huntington's Disease.

Andrade C, Beato J, Monteiro A, Costa A, Penas S, Guimarães J, Reis FF, Garrett C.

Mov Disord. 2016 Mar;31(3):377-83. doi: 10.1002/mds.26486. Epub 2016 Feb 8.

PMID:
26853218
19.

A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data.

Beste C, Stock AK, Ness V, Hoffmann R, Lukas C, Saft C.

Sci Rep. 2013;3:1797. doi: 10.1038/srep01797.

20.

Telomere Length in Leukocyte DNA in Gastric Cancer Patients and its Association with Clinicopathological Features and Prognosis.

Tahara T, Tahara S, Horiguchi N, Kawamura T, Okubo M, Ishizuka T, Yamada H, Yoshida D, Ohmori T, Maeda K, Komura N, Ikuno H, Jodai Y, Kamano T, Nagasaka M, Nakagawa Y, Tuskamoto T, Urano M, Shibata T, Kuroda M, Ohmiya N.

Anticancer Res. 2017 Apr;37(4):1997-2001.

PMID:
28373473

Supplemental Content

Support Center